Posted August 13, 2026 by NORD
WASHINGTON — In a major development for the nation’s public health and rare disease communities, the Health Resources and Services Administration (HRSA) has announced the formation of a National Newborn Screening Workgroup. The announcement, made public via the agency’s website ahead of an official Federal Register publication slated for August 12, 2026, marks a critical turning point for newborn healthcare oversight in the United States. Under this new initiative, the Association for Public Health Laboratories (APHL) has received a prestigious award from HRSA to re-establish a functional pathway for evaluating and recommending new conditions for inclusion on the prestigious Recommended Uniform Screening Panel (RUSP). Additionally, the newly formed workgroup will serve as a collaborative forum to address pressing nationwide issues currently impacting newborn screening programs across the country.
The establishment of this workgroup addresses a vital infrastructure need within the American healthcare system. The RUSP functions as an essential cornerstone of the nation’s newborn screening framework, offering authoritative, expert guidance to state-level health departments regarding which serious, treatable, and rare medical conditions should be incorporated into routine state newborn screening programs. By establishing a standardized federal benchmark, the RUSP plays an indispensable role in expanding early detection initiatives and prompt medical intervention. This early identification process is clinically proven to help prevent catastrophic diagnostic delays, significantly improve long-term health outcomes for affected infants, and, most importantly, save children’s lives. Without a consistent and reliable national advisory mechanism, individual states often face considerable challenges in keeping pace with rapid advancements in medical genetics, diagnostics, and pediatric pharmacology.
The creation of the HRSA-backed workgroup comes at a crucial juncture, arriving in the wake of significant administrative disruption within the federal oversight apparatus. In March 2025, the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) was dissolved, abruptly halting the longstanding federal process for reviewing and recommending new conditions for the RUSP. The sudden termination of the ACHDNC created widespread uncertainty regarding the future trajectory of the national newborn screening system, leaving patient advocacy organizations, medical professionals, and public health officials deeply concerned about potential bottlenecks in evaluating life-saving therapies for newborns. The newly announced National Newborn Screening Workgroup is explicitly designed to act as a continuation of the critical work previously performed by the ACHDNC in maintaining the integrity and advancement of the RUSP, thereby restoring much-needed stability and formal support to the national newborn screening program.
The rare disease community, spearheaded by organizations such as the National Organization for Rare Disorders (NORD), has greeted the announcement with a strong sense of relief and optimism. NORD has formally recognized the establishment of the National Newborn Screening Stakeholder Workgroup as an essential and highly anticipated step forward for the nation’s broader newborn screening program. For families navigating the complexities of rare pediatric conditions, the ability to secure early detection and prompt treatment for serious disorders is a matter of critical urgency. In the months following the dissolution of the prior advisory committee, NORD has been working diligently alongside a broad coalition of medical experts, clinical researchers, patient advocates, and government stakeholders to advance the foundational efforts formerly championed by the Advisory Committee on Heritable Disorders in Newborns and Children. With the Association for Public Health Laboratories now positioned to spearhead this transitional framework through the HRSA award, stakeholders are hopeful that the nation’s newborn screening enterprise will regain its momentum, ensuring that future generations of newborns have timely access to comprehensive, life-altering health screenings regardless of their state of birth.
